CMRX - Chimerix Inc Stock Price, Fair Value and News

$0.880.00 (0.00%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

CMRX Price Action

Last 7 days

-7.4%

Last 90 days

-12%

Trailing 12 Months

-8.3%

CMRX RSI Chart

CMRX Valuation

Market Cap

79.1M

Price/Earnings (Trailing)

-0.95

Price/Sales (Trailing)

263.7

EV/EBITDA

0.33

Price/Free Cashflow

-1.12

CMRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CMRX Fundamentals

CMRX Revenue

Revenue (TTM)

324.0K

Rev. Growth (Yr)

73.33%

Rev. Growth (Qtr)

-79.84%

CMRX Earnings

Earnings (TTM)

-83.6M

Earnings Growth (Yr)

4.62%

Earnings Growth (Qtr)

-10.61%

CMRX Profitability

Operating Margin

100.00%

EBT Margin

55028.09%

Return on Equity

-61.57%

Return on Assets

-52.68%

Free Cashflow Yield

-88.98%

CMRX Investor Care

Shares Dilution (1Y)

1.18%

Diluted EPS (TTM)

-0.95

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	25.4M	17.1M	8.7M	324.0K
2022	9.9M	17.9M	25.9M	33.8M
2021	5.6M	4.6M	3.1M	2.0M
2020	10.7M	8.9M	7.2M	5.4M
2019	8.8M	9.0M	10.6M	11.6M
2018	4.2M	4.7M	4.2M	7.2M
2017	5.6M	4.4M	4.6M	4.5M
2016	10.8M	8.4M	6.8M	5.7M
2015	4.5M	7.7M	8.8M	10.8M
2014	3.4M	3.5M	3.8M	4.0M
2013	32.4M	27.0M	7.1M	4.4M
2012	17.5M	22.9M	28.3M	33.7M
2011	0	0	0	12.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About Chimerix Inc

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 2 clinical trial for treating tumors, which harbor the H3 K27M mutation in glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2 (COVID-19) infection. The company has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

CEO	Mr. Michael T. Andriole M.B.A.
WEBSITE	chimerix.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	89

Chimerix Inc Frequently Asked Questions

What is the ticker symbol for Chimerix Inc? What does CMRX stand for in stocks?

CMRX is the stock ticker symbol of Chimerix Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Chimerix Inc (CMRX)?

As of Wed Nov 20 2024, market cap of Chimerix Inc is 79.14 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CMRX stock?

You can check CMRX's fair value in chart for subscribers.

Is Chimerix Inc a good stock to buy?

The fair value guage provides a quick view whether CMRX is over valued or under valued. Whether Chimerix Inc is cheap or expensive depends on the assumptions which impact Chimerix Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CMRX.

What is Chimerix Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Nov 20 2024, CMRX's PE ratio (Price to Earnings) is -0.95 and Price to Sales (PS) ratio is 263.7. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CMRX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Chimerix Inc's stock?

In the past 10 years, Chimerix Inc has provided -0.308 (multiply by 100 for percentage) rate of return.